Gastrointestinal Hormones and Neurotransmitters

Sleisenger and Fordtran’s Gastrointestinal and Liver Disease- 2 Volume Set: Pathophysiology, Diagnosis, Management, Expert Consult Premium Edition - Enhanced Online Features and Print

Volumn , Issue , 2010, Pages 3-19

  Liddle, Rodger A ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85124852449     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6189-2.00001-9     Document Type: Chapter

References (194)

1. Batterham RL., Cowley MA., Small CJ., et al. Gut hormone PYY(3-36) physiologically inhibits food intake Nature 418 2002 650-654 (Ref 60.).
2. Boehning D., Snyder SH Novel neural modulators Annu Rev Neurosci 26 2003 105-131 (Ref 119.).
3. Burdick JS., Chung E., Tanner G., et al. Treatment of Ménétrier’s disease with a monoclonal antibody against the epidermal growth factor receptor N Engl J Med 343 2000 1697-1701 (Ref 142.).
4. Cummings DE., Weigle DS., Frayo RS., et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery N Engl J Med 346 2002 1623-1630 (Ref 100.).
5. de Herder WW., Lamberts SW Somatostatin and somatostatin analogues: Diagnostic and therapeutic uses Curr Opin Oncol 14 2002 53-57 (Ref 75.).
6. Drucker DJ Enhancing incretin action for the treatment of type 2 diabetes Diabetes Care 26 2003 2929-2940 (Ref 175.).
7. Joseph IM., Zavros Y., Merchant JL., Kirschner D A model for integrative study of human gastric acid secretion J Appl Physiol 94 2003 1602-1618 (Ref 70.).
8. Miyawaki K., Yamada Y., Ban N., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity Nat Med 8 2002 738-742 (Ref 48.).
9. Nakazato M., Murakami N., Date Y., et al. A role for ghrelin in the central regulation of feeding Nature 409 2001 194-198 (Ref 94.).
10. Pennefather JN., Lecci A., Candenas ML., et al. Tachykinins and tachykinin receptors: a growing family Life Sci 74 2004 1445-1463 (Ref 65.).
11. Schlessinger J Cell signaling by receptor tyrosine kinases Cell 103 2000 211-225 (Ref 133.).
12. Thomas RP., Hellmich MR., Townsend CM Jr., Evers BM Role of GI hormones in the proliferation of normal and neoplastic tissues Endocr Rev 24 2003 571-599 (Ref 73.).
13. Tracey KJ The inflammatory reflex Nature 420 2002 853-859 (Ref 123.).
14. Vilsboll T., Zdravkovic M., Le-Thi T., et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes Diabetes Care 30 2007 1608-1610 (Ref 44.).
15. Woods SC GI satiety signals I. An overview of GI signals that influence food intake Am J Physiol Gastrointest Liver Physiol 286 2004 G7-13 (Ref 163.).
16. Del Valle J., Yamada T The gut as an endocrine organ Annu Rev Med 41 1990 447-455.
17. Larsson LI., Goltermann N., de Magistris L., et al. Somatostatin cell processes as pathways for paracrine secretion Science 205 1979 1393-1395.
18. Grabowska AM., Watson SA Role of gastrin peptides in carcinogenesis Cancer Lett 257 2007 1-15.
19. Gershon V MD Genes, lineages, and tissue interactions in the development of the enteric nervous system Am J Physiol 275 Pt 1 1998 G869-G873.
20. Dockray GJ Physiology of enteric neuropeptides In: Johnson LR Physiology of the GI tract 1994 Raven Press New York 129.
21. Murthy KS., Grider JR., Jin JG., Makhlouf GM Interplay of VIP and nitric oxide in the regulation of neuromuscular activity in the gut Arch Int Pharmacodyn Ther 329 1995 27-38.
22. Furness JB., Clerc N Responses of afferent neurons to the contents of the digestive tract, and their relation to endocrine and immune responses Prog Brain Res 122 2000 159-172.
23. Smith GP., Gibbs J Satiating effect of cholecystokinin Ann N Y Acad Sci 713 1994 236-241.
24. Corsi AK., Schekman R Mechanism of polypeptide translocation into the endoplasmic reticulum J Biol Chem 271 1996 30299-30302.
25. Rehfeld JF Processing of precursors of gastroenteropancreatic hormones: Diagnostic significance J Mol Med 76 1998 338-345.
26. Velander WH., Lubon H., Drohan WN Transgenic livestock as drug factories Sci Am 276 1997 70-74.
27. Crooke ST Progress in antisense technology Annu Rev Med 55 2004 61-95.
28. Kim PS., Arvan P Endocrinopathies in the family of endoplasmic reticulum (ER) storage diseases: Disorders of protein trafficking and the role of ER molecular chaperones Endocr Rev 19 1998 173-202.
29. Liu X., Jiang Q., Mansfield SG., et al. Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing Nat Biotechnol 20 2002 47-52.
30. Joshi SN., Gardner JD Gastrin and colon cancer: A unifying hypothesis Dig Dis 14 1996 334-344.
31. Aly A., Shulkes A., Baldwin GS Gastrins, cholecystokinins and GI cancer Biochim Biophys Acta 1704 2004 1-10.
32. Rehfeld JF The new biology of GI hormones Physiol Rev 78 1998 1087-1108.
33. Kopin AS., Lee YM., McBride EW., et al. Expression cloning and characterization of the canine parietal cell gastrin receptor Proc Natl Acad Sci U S A 89 1992 3605-3609.
34. Liddle RA Cholecystokinin In: Walsh JH., Dockray GJ Gut peptides: Biochemistry and physiology 1994 Raven Press New York 175.
35. Reeve JR Jr., Eysselein VE., Ho FJ., et al. Natural and synthetic CCK-58. Novel reagents for studying cholecystokinin physiology Ann N Y Acad Sci 713 1994 11-21.
36. Liddle RA., Morita ET., Conrad CK., Williams JA Regulation of gastric emptying in humans by cholecystokinin J Clin Invest 77 1986 992-996.
37. Schmitz F., Göke MN., Otte JM., et al. Cellular expression of CCK-A and CCK-B/gastrin receptors in human gastric mucosa Regul Pept 102 2001 101-110.
38. Calam J., Ellis A., Dockray GJ Identification and measurement of molecular variants of cholecystokinin in duodenal mucosa and plasma. Diminished concentrations in patients with celiac disease J Clin Invest 69 1982 218-225.
39. Geracioti TD Jr., Liddle RA Impaired cholecystokinin secretion in bulimia nervosa N Engl J Med 319 1988 683-688.
40. Slaff JI., Wolfe MM., Toskes PP Elevated fasting cholecystokinin levels in pancreatic exocrine impairment: Evidence to support feedback regulation J Lab Clin Med 105 1985 282-285.
41. Bayliss WM., Starling EH The mechanism of pancreatic secretion J Physiol 28 1902 325-353.
42. Leiter AB., Chey WY., Kopin AS Secretin In: Walsh JH., Dockray GJ Gut peptides: Biochemistry and physiology 1994 Raven Press New York 144.
43. Li P., Lee KY., Chang TM., Chey WY Mechanism of acid-induced release of secretin in rats. Presence of a secretin-releasing peptide J Clin Invest 86 1990 1474-1479.
44. You CH., Chey WY Secretin is an enterogastrone in humans Dig Dis Sc 32 1987 466-471.
45. McGuigan JE., Wolfe MM Secretin injection test in the diagnosis of gastrinoma Gastroenterology 79 1980 1324-1331.
46. Said SI., Mutt V Polypeptide with broad biological activity: Isolation from small intestine Science 169 1970 1217-1218.
47. Dockray GJ Vasoactive intestinal polypeptide and related peptides In: Walsh JH., Dockray GJ Gut peptides: Biochemistry and physiology 1994 Raven Press New York 447.
48. Holst JJ., Fahrenkrug J., Knuhtsen S., et al. VIP and PHI in the pig pancreas: Coexistence, corelease, and cooperative effects Am J Physiol 252 Pt 1 1987 G182-G189.
49. Fahrenkrug J Transmitter role of vasoactive intestinal peptide Pharmacol Toxicol 72 1993 354-363.
50. Bloom SR Vasoactive intestinal peptide, the major mediator of the WDHA (pancreatic cholera) syndrome: Value of measurement in diagnosis and treatment Am J Dig Dis 23 1978 373-376.
51. Cho WK., Boyer JL Vasoactive intestinal polypeptide is a potent regulator of bile secretion from rat cholangiocytes Gastroenterology 117 1999 420-428.
52. Grider JR Interplay of VIP and nitric oxide in regulation of the descending relaxation phase of peristalsis Am J Physiol 264 Pt 1 1993 G334-G340.
53. Aggestrup S., Uddman R., Sundler F., et al. Lack of vasoactive intestinal polypeptide nerves in esophageal achalasia Gastroenterology 84 Pt 1 1983 924-927.
54. Larsson LT., Sundler F Is the reduction of VIP the clue to the pathophysiology of Hirschsprung’s disease? Z Kinderchir 45 1990 164-166.
55. Verner JV., Morrison AB Endocrine pancreatic islet disease with diarrhea. Report of a case due to diffuse hyperplasia of nonbeta islet tissue with a review of 54 additional cases Arch Intern Med 133 1974 492-499.
56. Smith SL., Branton SA., Avino AJ., et al. Vasoactive intestinal polypeptide secreting islet cell tumors: A 15-year experience and review of the literature Surgery 124 1998 1050-1055.
57. Mojsov S., Heinrich G., Wilson IB., et al. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing J Biol Chem 261 1986 11880-11889.
58. Drucker DJ. Glucagon-like peptides Diabetes 47 1998 159-169.
59. Vilsboll T., Zdravkovic M., Le-Thi T., et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes Diabetes Care 30 2007 1608-1610.
60. Vilsboll T., Brock B., Perrild H., et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus Diabet Med 25 2008 152-156.
61. Pederson RA Gastric inhibitory polypeptide In: Walsh JH., Dockray GJ Gut peptides: Biochemistry and physiology 1994 Raven Press New York 217.
62. Kieffer TJ GIP or not GIP? That is the question Trends Pharmacol Sci 24 2003 110-112.
63. Miyawaki K., Yamada Y., Ban N., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity Nat Med 8 2002 738-742.
64. Lacroix A., Bolte E., Tremblay J., et al. Gastric inhibitory polypeptide-dependent cortisol hypersecretion-a new cause of Cushing’s syndrome N Engl J Med 327 1992 974-980.
65. Reznik Y., Allali-Zerah V., Chayvialle JA., et al. Food-dependent Cushing’s syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide N Engl J Med 327 1992 981-986.
66. Kimmel JR., Hayden LJ., Pollock HG Isolation and characterization of a new pancreatic polypeptide hormone J Biol Chem 250 1975 9369-9376.
67. Tatemoto K., Mutt V Chemical determination of polypeptide hormones Proc Natl Acad Sci U S A 75 1978 4115-4119.
68. Tatemoto K., Carlquist M., Mutt V Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide Nature 296 1982 659-660.
69. Larsson LI., Sundler F., Hakanson R Pancreatic polypeptide-a postulated new hormone: Identification of its cellular storage site by light and electron microscopic immunocytochemistry Diabetologia 12 1976 211-226.
70. Wahlestedt C., Reis DJ Neuropeptide Y-related peptides and their receptors-are the receptors potential therapeutic drug targets? Annu Rev Pharmacol Toxicol 33 1993 309-352.
71. Lundberg JM., Tatemoto K., Terenius L., et al. Localization of peptide YY (PYY) in GI endocrine cells and effects on intestinal blood flow and motility Proc Natl Acad Sci U S A 79 1982 4471-4475.
72. Gehlert DR Multiple receptors for the pancreatic polypeptide (PP-fold) family: Physiological implications Proc Soc Exp Biol Med 218 1998 7-22.
73. Mannon P., Taylor IL The pancreatic polypeptide family In: Walsh JH., Dockray GJ Gut peptides: Biochemistry and physiology 1994 Raven Press New York 341.
74. Lloyd KC., Grandt D., Aurang K., et al. Inhibitory effect of PYY on vagally stimulated acid secretion is mediated predominantly by Y1 receptors Am J Physiol 270 Pt 1 1996 G123-G127.
75. Batterham RL., Cowley MA., Small CJ., et al. Gut hormone PYY(3-36) physiologically inhibits food intake Nature 418 2002 650-654.
76. Hwa JJ., Witten MB., Williams P., et al. Activation of the NPY Y5 receptor regulates both feeding and energy expenditure Am J Physiol 277 Pt 2 1999 R1428-R1434.
77. Hazelwood RL The pancreatic polypeptide (PP-fold) family: Gastrointestinal, vascular, and feeding behavioral implications Proc Soc Exp Biol Med 202 1993 44-63.
78. Cao T., Pinter E., Al-Rashed S., et al. Neurokinin-1 receptor agonists are involved in mediating neutrophil accumulation in the inflamed, but not normal, cutaneous microvasculature: An in vivo study using neurokinin-1 receptor knockout mice J Immunol 164 2000 5424-5429.
79. Mantyh PW., DeMaster E., Malhotra A., et al. Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation Science 268 1995 1629-1632.
80. Pennefather JN., Lecci A., Candenas ML., et al. Tachykinins and tachykinin receptors: A growing family Life Sci 74 2004 1445-1463.
81. Mantyh CR., Pappas TN., Lapp JA., et al. Substance P activation of enteric neurons in response to intraluminal Clostridium difficile toxin A in the rat ileum Gastroenterology 111 1996 1272-1280.
82. Mantyh PW., Mantyh CR., Gates T., et al. Receptor binding sites for substance P and substance K in the canine gastrointestinal tract and their possible role in inflammatory bowel disease NeuroScience 25 1988 817-837.
83. Chiba T., Yamada T Gut somatostatin In: Walsh JH., Dockray GJ Gut peptides: Biochemistry and physiology 1994 Raven Press New York 123.
84. Kolivas S., Shulkes A Regulation of expression of the receptors controlling gastric acidity Regul Pept 121 2004 1-9.
85. Joseph IM., Zavros Y., Merchant JL., Kirschner D A model for integrative study of human gastric acid secretion J Appl Physiol 94 2003 1602-1618.
86. Patel YC., Greenwood MT., Panetta R., et al. The somatostatin receptor family Life Sci 57 1995 1249-1265.
87. Chey WY., Chang T Neural hormonal regulation of exocrine pancreatic secretion Pancreatology 1 2001 320-335.
88. Thomas RP., Hellmich MR., Townsend CM Jr., Evers BM Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues Endocr Rev 24 2003 571-599.
89. Florio T Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors Front Biosci 13 2008 822-840.
90. de Herder WW., Lamberts SW Somatostatin and somatostatin analogues: Diagnostic and therapeutic uses Curr Opin Oncol 14 2002 53-57.
91. de Franchis R Somatostatin, somatostatin analogues and other vasoactive drugs in the treatment of bleeding oesophageal varices Dig Liver Dis 36 Suppl 1 2004 S93-100.
92. Poitras P Motilin In: Walsh JH., Dockray GJ Gut peptides: Biochemistry and physiology 1994 Raven Press New York 261.
93. Depoortere I Motilin and motilin receptors: characterization and functional significance Verh K Acad Geneeskd Belg 63 2001 511-529.
94. Pilot MA Macrolides in roles beyond antibiotic therapy Br J Surg 81 1994 1423-1429.
95. Itoh Z Motilin and clinical application Peptides 18 1997 593-608.
96. Zhang Y., Proenca R., Maffei M., et al. Positional cloning of the mouse obese gene and its human homologue Nature 372 1994 425-432.
97. Tartaglia LA., Dembski M., Weng X., et al. Identification and expression cloning of a leptin receptor, OB-R Cell 83 1995 1263-1271.
98. Vaisse C., Halaas JL., Horvath CM., et al. Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice Nat Genet 14 1996 95-97.
99. Banks WA., Kastin AJ., Huang W., et al. Leptin enters the brain by a saturable system independent of insulin Peptides 17 1996 305-311.
100. Schwartz MW., Seeley RJ., Campfield LA., et al. Identification of targets of leptin action in rat hypothalamus J Clin Invest 98 1996 1101-1106.
101. Lewin MJ., Bado A Gastric leptin Microsc Res Tech 53 2001 372-376.
102. Morton GJ., Blevins JE., Williams DL., et al. Leptin action in the forebrain regulates the hindbrain response to satiety signals J Clin Invest 115 2005 703-710.
103. Ostlund RE Jr., Yang JW., Klein S., Gingerich R Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates J Clin Endocrinol Metab 81 1996 3909-3913.
104. Montague CT., Farooqi IS., Whitehead JP., et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans Nature 387 1997 903-908.
105. Strobel A., Issad T., Camoin L., et al. A leptin missense mutation associated with hypogonadism and morbid obesity Nat Genet 18 1998 213-215.
106. Clement K., Vaisse C., Lahlou N., et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction Nature 392 1998 398-401.
107. Kojima M., Hosoda H., Date Y., et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach Nature 402 1999 656-660.
108. Takaya K., Ariyasu H., Kanamoto N., et al. Ghrelin strongly stimulates growth hormone release in humans J Clin Endocrinol Metab 85 2000 4908-4911.
109. Nakazato M., Murakami N., Date Y., et al. A role for ghrelin in the central regulation of feeding Nature 409 2001 194-198.
110. Ariyasu H., Takaya K., Tagami T., et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans J Clin Endocrinol Metab 86 2001 4753-4758.
111. Date Y., Kojima M., Hosoda H., et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans Endocrinology 141 2000 4255-4261.
112. Hosoda H., Kojima M., Kangawa K Ghrelin and the regulation of food intake and energy balance Mol Interv 2 2002 494-503.
113. Tschop M., Weyer C., Tataranni PA., et al. Circulating ghrelin levels are decreased in human obesity Diabetes 50 2001 707-709.
114. Otto B., Cuntz U., Fruehauf E., et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa Eur J Endocrinol 145 2001 669-673.
115. Cummings DE., Weigle DS., Frayo RS., et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery N Engl J Med 346 2002 1623-1630.
116. Kamegai J., Tamura H., Shimizu T., et al. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats Diabetes 50 2001 2438-2443.
117. Inui A., Asakawa A., Bowers CY., et al. Ghrelin, appetite, and gastric motility: The emerging role of the stomach as an endocrine organ FASEB J 18 2004 439-456.
118. Cummings DE., Clement K., Purnell JQ., et al. Elevated plasma ghrelin levels in Prader Willi syndrome Nat Med 8 2002 643-644.
119. DelParigi A., Tschop M., Heiman ML., et al. High circulating ghrelin: A potential cause for hyperphagia and obesity in Prader-Willi syndrome J Clin Endocrinol Metab 87 2002 5461-5464.
120. Wren AM., Seal LJ., Cohen MA., et al. Ghrelin enhances appetite and increases food intake in humans J Clin Endocrinol Metab 86 2001 5992.
121. Dajas-Bailador F., Wonnacott S Nicotinic acetylcholine receptors and the regulation of neuronal signalling Trends Pharmacol Sci 25 2004 317-324.
122. Velasco M., Luchsinger A Dopamine: Pharmacologic and therapeutic aspects Am J Ther 5 1998 37-43.
123. Missale C., Nash SR., Robinson SW., et al. Dopamine receptors: From structure to function Physiol Rev 78 1998 189-225.
124. Gershon MD Review article: Roles played by 5-hydroxytryptamine in the physiology of the bowel Aliment Pharmacol Ther 13 Suppl 2 1999 15-30.
125. Kim DY., Camilleri M Serotonin: A mediator of the brain-gut connection Am J Gastroenterol 95 2000 2698-2709.
126. Talley NJ Serotoninergic neuroenteric modulators Lancet 358 2001 2061-2068.
127. Pandolfino JE., Howden CW., Kahrilas PJ Motility-modifying agents and management of disorders of gastrointestinal motility Gastroenterology 118 Suppl 1 2000 S32-S47.
128. Camilleri M Management of the irritable bowel syndrome Gastroenterology 120 2001 652-668.
129. Bouras EP., Camilleri M., Burton DD., et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder Gastroenterology 120 2001 354-360.
130. Zheng W., Cole PA Serotonin N-acetyltransferase: Mechanism and inhibition Curr Med Chem 9 2002 1187-1199.
131. Bubenik GA Localization, physiological significance and possible clinical implication of gastrointestinal melatonin Biol Signals Recept 10 2001 350-366.
132. Bazar KA., Yun AJ., Lee PY Debunking a myth: Neurohormonal and vagal modulation of sleep centers, not redistribution of blood flow, may account for postprandial somnolence Med Hypotheses 63 2004 778-782.
133. Hill SJ., Ganellin CR., Timmerman H., et al. International Union of Pharmacology. XIII. Classification of histamine receptors Pharmacol Rev 49 1997 253-278.
134. Boehning D., Snyder SH Novel neural modulators Annu Rev Neurosci 26 2003 105-131.
135. Bornstein JC., Costa M., Grider JR Enteric motor and interneuronal circuits controlling motility Neurogastroenterol Motil 16 Suppl 1 2004 34-38.
136. Wallace JL., Miller MJ Nitric oxide in mucosal defense: A little goes a long way Gastroenterology 119 2000 512-520.
137. Schulte G., Fredholm BB Signalling from adenosine receptors to mitogen-activated protein kinases Cell Signal 15 2003 813-827.
138. Tracey KJ The inflammatory reflex Nature 420 2002 853-859.
139. Lefkowitz RJ The superfamily of heptahelical receptors Nat Cell Biol 2 2000 E133-E136.
140. Palczewski K., Kumasaka T., Hori T., et al. Crystal structure of rhodopsin: A G protein-coupled receptor Science 289 2000 739-745.
141. Patel TB Single transmembrane spanning heterotrimeric G protein-coupled receptors and their signaling cascades Pharmacol Rev 56 2004 371-385.
142. Pierce KL., Premont RT., Lefkowitz RJ Seven-transmembrane receptors Nat Rev Mol Cell Biol 3 2002 639-650.
143. Simonds WF G protein regulation of adenylate cyclase Trends Pharmacol Sci 20 1999 66-73.
144. Robishaw JD., Berlot CH Translating G protein subunit diversity into functional specificity Curr Opin Cell Biol 16 2004 206-209.
145. Clapham DE., Neer EJ G protein beta gamma subunits Annu Rev Pharmacol Toxicol 37 1997 167-203.
146. Litosch I Novel mechanisms for feedback regulation of phospholipase C-beta activity IUBMB Life 54 2002 253-260.
147. Kohout TA., Lefkowitz RJ Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization Mol Pharmacol 63 2003 9-18.
148. Schlessinger J Cell signaling by receptor tyrosine kinases Cell 103 2000 211-225.
149. Simon MA Receptor tyrosine kinases: Specific outcomes from general signals Cell 103 2000 13-15.
150. Pawson T Specificity in signal transduction: From phosphotyrosine-SH2 domain interactions to complex cellular systems Cell 116 2004 191-203.
151. Kuhn M Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A Circ Res 93 2003 700-709.
152. Yeatman TJ A renaissance for SRC Nat Rev Cancer 4 2004 470-480.
153. Irie-Sasaki J., Sasaki T., Penninger JM CD45-regulated signaling pathways Curr Top Med Chem 3 2003 783-796.
154. Shi Y., Massague J Mechanisms of TGF-beta signaling from cell membrane to the nucleus Cell 113 2003 685-700.
155. Podolsky DK Peptide growth factors in the gastrointestinal tract In: Johnson LR Physiology of the gastrointestinal tract 1994 Raven Press New York 129.
156. Zimmerman CM., Padgett RW Transforming growth factor beta signaling mediators and modulators Gene 249 2000 17-30.
157. Burdick JS., Chung E., Tanner G., et al. Treatment of Ménétrier’s disease with a monoclonal antibody against the epidermal growth factor receptor N Engl J Med 343 2000 1697-1701.
158. Settle SH., Washington K., Lind C., et al. Chronic treatment of Ménétrier’s disease with Erbitux: Clinical efficacy and insight into pathophysiology Clin Gastroenterol Hepatol 3 2005 654-659.
159. Caraglia M., Marra M., Meo G., Addeo SR., et al. EGF-R small inhibitors and anti-EGF-R antibodies: Advantages and limits of a new avenue in anticancer therapy. Recent Patents Anticancer Drug Discov 1 2006 209-222.
160. Massague J How cells read TGF-beta signals Nat Rev Mol Cell Biol 1 2000 169-178.
161. Williams RS., Rossi AM., Chegini N., Schultz G Effect of transforming growth factor beta on postoperative adhesion formation and intact peritoneum J Surg Res 52 1992 65-70.
162. Adams TE., Epa VC., Garrett TP., Ward CW Structure and function of the type 1 insulin-like growth factor receptor Cell Mol Life Sci 57 2000 1050-1093.
163. Ornitz DM FGFs, heparan sulfate and FGFRs: Complex interactions essential for development Bioessays 22 2000 108-112.
164. Kim SK., MacDonald RJ Signaling and transcriptional control of pancreatic organogenesis Curr Opin Genet Dev 12 2002 540-547.
165. Podolsky DK Mechanisms of regulatory peptide action in the gastrointestinal tract: Trefoil peptides J Gastroenterol 35 Suppl 12 2000 69-74.
166. Koh TJ., Chen D Gastrin as a growth factor in the gastrointestinal tract Regul Pept 93 2000 37-44.
167. Smith AM., Watson SA Gastrin and gastrin receptor activation: An early event in the adenoma-carcinoma sequence Gut 47 2000 820-824.
168. Hildebrand P., Lehmann FS., Ketterer S., et al. Regulation of gastric function by endogenous gastrin-releasing peptide in humans: Studies with a specific gastrin-releasing peptide antagonist Gut 49 2001 23-28.
169. Schally AV., Szepeshazi K., Nagy A., et al. New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs Cell Mol Life Sci 61 2004 1042-1068.
170. Sternini C Taste receptors in the gastrointestinal tract. IV. Functional implications of bitter taste receptors in gastrointestinal chemosensing Am J Physiol Gastrointest Liver Physiol 292 2007 G457-G461.
171. Rozengurt E., Sternini C Taste receptor signaling in the mammalian gut Curr Opin Pharmacol 7 2007 557-562.
172. Hofer D., Asan E., Drenckhahn D Chemosensory perception in the gut News Physiol Sci 14 1999 18-23.
173. Spannagel AW., Green GM., Guan D., et al. Purification and characterization of a luminal cholecystokinin-releasing factor from rat intestinal secretion Proc Natl Acad Sci U S A 93 1996 4415-4420.
174. Herzig KH., Schon I., Tatemoto K., et al. Diazepam binding inhibitor is a potent cholecystokinin-releasing peptide in the intestine Proc Natl Acad Sci U S A 93 1996 7927-7932.
175. Iwai K., Fukuoka S., Fushiki T., et al. Purification and sequencing of a trypsin-sensitive cholecystokinin-releasing peptide from rat pancreatic juice. Its homology with pancreatic secretory trypsin inhibitor J Biol Chem 262 1987 8956-8959.
176. Li Y., Hao Y., Owyang C Diazepam-binding inhibitor mediates feedback regulation of pancreatic secretion and postprandial release of cholecystokinin J Clin Invest 105 2000 351-359.
177. Cummings DE., Overduin J Gastrointestinal regulation of food intake J Clin Invest 117 2007 13-23.
178. Woods SC GI satiety signals I. An overview of GI signals that influence food intake Am J Physiol Gastrointest Liver Physiol 286 2004 G7-13.
179. Moran TH., Kinzig KP Gastrointestinal satiety signals II. Cholecystokinin Am J Physiol Gastrointest Liver Physiol 286 2004 G183-G188.
180. Ritter RC., Covasa M., Matson CA Cholecystokinin: Proofs and prospects for involvement in control of food intake and body weight Neuropeptides 33 1999 387-399.
181. Stanley S., Wynne K., Bloom S Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide Am J Physiol Gastrointest Liver Physiol 286 2004 G693-G697.
182. Sainsbury A., Schwarzer C., Couzens M., et al. Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice Proc Natl Acad Sci U S A 99 2002 8938-8943.
183. Batterham RL., Cohen MA., Ellis SM., et al. Inhibition of food intake in obese subjects by peptide YY3-36 N Engl J Med 349 2003 941-948.
184. Korbonits M., Goldstone AP., Gueorguiev M., Grossman AB Ghrelin-a hormone with multiple functions Front Neuroendocrinol 25 2004 27-68.
185. Korner J., Bessler M., Cirilo LJ., et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin J Clin Endocrinol Metab 90 2005 359-365.
186. Perfetti R., Brown TA., Velikina R., Busselen S Control of glucose homeostasis by incretin hormones Diabetes Technol Ther 1 1999 297-305.
187. Fehmann HC., Gherzi R., Goke B Regulation of islet hormone gene expression by incretin hormones Exp Clin Endocrinol Diabetes 103 Suppl 2 1995 56-65.
188. Fehmann HC., Goke R., Goke B Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin-releasing polypeptide Endocr Rev 16 1995 390-410.
189. Reda TK., Geliebter A., Pi-Sunyer FX Amylin, food intake, and obesity Obes Res 10 2002 1087-1091.
190. Drucker DJ Enhancing incretin action for the treatment of type 2 diabetes Diabetes Care 26 2003 2929-2940.
191. Vilsboll T., Agerso H., Krarup T., Holst JJ Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects J Clin Endocrinol Metab 88 2003 220-224.
192. Ahren B Gut peptides and type 2 diabetes mellitus treatment Curr Diab Rep 3 2003 365-372.
193. Ranganath LR Incretins: Pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 J Clin Pathol 61 2008 401-409.
194. Raz I., Hanefeld M., Xu L., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitaglyptin as monotheapy in patients with typer 2 diabetes mellitus Diabetologia 49 2006 2564-2571.